Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 997 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inhibition Clear all
Completed Phase 2 Interventional Results available

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss

NCT06029673
View directory record Official record
Conditions
Lactation Suppressed
Interventions
Cabergoline 1 MG, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

NCT02821754
View directory record Official record
Conditions
Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
Interventions
Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), Cryoablation
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 18, 2026, 2:56 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

NCT01990196
View directory record Official record
Conditions
Prostate Cancer
Interventions
degarelix, enzalutamide, trametinib, dasatinib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 18, 2026, 2:56 AM EDT
Recruiting Phase 3 Interventional

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

NCT05135091
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
NRTX-1001, Sham Comparator
Biological · Procedure
Lead sponsor
Neurona Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2043
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Early Phase 1 Interventional Results available

Losartan for Improved Vascular Endothelial Function After Preeclampsia

NCT04632589
View directory record Official record
Conditions
Preeclampsia Postpartum
Interventions
Losartan Potassium, Placebo
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

NCT03732352
View directory record Official record
Conditions
EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, TP53 Wt Allele
Interventions
Fludeoxyglucose F-18, Osimertinib, Positron Emission Tomography
Other · Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 18, 2026, 2:56 AM EDT
Recruiting Phase 1 Interventional

Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial

NCT06834126
View directory record Official record
Conditions
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Consolidation Therapy, Functional Magnetic Resonance Imaging, Gastrointestinal Endoscopy, Magnetic Resonance Imaging, Papaverine, Radiation Therapy, Total Mesorectal Excision
Procedure · Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 18, 2026, 2:56 AM EDT
Recruiting Phase 2 Interventional

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

NCT06364917
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, Nivolumab, Ipilimumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 4 Interventional

D-Cycloserine for Serine Palmitoyltransferase Inhibition

NCT07542548
View directory record Official record
Conditions
Hereditary Spastic Paraplegia
Interventions
D-cycloserine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 6 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 18, 2026, 2:56 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Immunomodulatory Effects of PCSK9 Inhibition

NCT05720156
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, Atherosclerosis, Arterial Inflammation, Vascular Diseases, Vascular Disease, Peripheral, Vascular Calcification, High Cholesterol/Hyperlipidemia, Heart Diseases, Heart Attack, Stroke, Cerebrovascular Accident, Carotid Artery Diseases, Carotid Atherosclerosis, Transient Ischemic Attack
Interventions
99mTc-tilmanocept SPECT/CT scanning
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Emotional Processes on Speech Motor Control in Early Childhood Stuttering.

NCT05003583
View directory record Official record
Conditions
Stuttering, Childhood
Interventions
Speaking after viewing pictures with negative and neutral valence
Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
3 Years to 10 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

NCT03417245
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
fitusiran, factor concentrates
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
12 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 18, 2026, 2:56 AM EDT
Terminated Phase 3 Interventional Results available

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

NCT00991029
View directory record Official record
Conditions
Ischemic Attack, Transient
Interventions
Clopidogrel, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
4,881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
147
States / cities
Chandler, Arizona • Tucson, Arizona • Carmichael, California + 95 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 18, 2026, 2:56 AM EDT
Not yet recruiting Phase 2 Interventional

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

NCT07015853
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions
Pembrolizumab, Radiotherapy, Axatilimab
Drug · Radiation
Lead sponsor
Stephen Shiao
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)

NCT00115375
View directory record Official record
Conditions
Congenital Heart Defects, Blood Platelet Disorders
Interventions
Clopidogrel (SR25990)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Up to 24 Months
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)

NCT00763867
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Sildenafil
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

NCT03065400
View directory record Official record
Conditions
Chronic Phase Myelofibrosis, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
Interventions
Pembrolizumab
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 18, 2026, 2:56 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT05019521
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Danicopan, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
49
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

NCT00567164
View directory record Official record
Conditions
Contraception, Ovulation Inhibition, Contraceptives, Oral
Interventions
EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,887 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
85
States / cities
Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

NCT07158411
View directory record Official record
Conditions
Healthy Participants
Interventions
Vimseltinib, Metformin
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

NCT03723395
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
tucatinib, itraconazole, rifampin, gemfibrozil, repaglinide, tolbutamide, midazolam, digoxin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial

NCT03374800
View directory record Official record
Conditions
Gastrointestinal Hemorrhage (Clinically Important, Upper)
Interventions
Placebo (0.9% saline), Pantoprazole
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
4,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 18, 2026, 2:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

EEG and EMG Studies of Hand Dystonia

NCT00025701
View directory record Official record
Conditions
Focal Dystonia
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 2:56 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury

NCT03273062
View directory record Official record
Conditions
Brain Injuries, Brain Injuries, Traumatic, Brain Injury, Chronic
Interventions
Tolcapone 200 MG, Placebo
Drug · Other
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 18, 2026, 2:56 AM EDT